**Message from the Guest Editor**

Dear Colleagues,

This Special Issue is about the unique tumor suppressor p53. The exclusivity of this gene begins from its discovery—it was originally believed to be an oncogene, but genetic and functional data obtained ten years after its discovery showed it to be a powerful natural tumor suppressor. The most commonly-mutated gene in cancer, a major responder to stress conditions, and a potent regulator of transcription and a strong player in signaling to apoptosis, p53 became one of the most attractive molecular targets in cancer therapy; together with p53 animal models, p53 reactivating molecules, in turn, appeared to be a great tool to study p53 cellular functions. Recently-discovered p53 activities in metabolism, immunity, epigenetic regulation and non-apoptotic cell death evidently showed that we are still far away from a clear understanding of how p53 exerts its tumors suppressor functions. Here, we welcome papers outlining mechanisms of p53 control and p53 roles in cancer and normal tissues.

Dr. Issaeva Natalia  
*Guest Editor*
Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews. Citations available in PubMed, full-text archived in PubMed Central. Indexed in BIOSIS Previews, Scopus and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 16.9 days after submission; acceptance to publication is undertaken in 4.2 days (median values for papers published in this journal in the second half of 2018).

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI